Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 17

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 17
---
,
to a third party, or to liquidate it during 2025.

An important element of our strategy is maintaining relationships
with universities, medical institutions and biotechnology companies in order to in-license potential therapeutic candidates. We may not
be able to maintain relationships with these entities, and they may elect not to enter into in-licensing agreements with us or to terminate
existing agreements. The existence of global companies with significantly greater resources than we have may increase the competition
with respect to the in-licensing of promising therapeutic candidates. We may not be able to acquire licenses on commercially reasonable
terms or at all. Failure to license or otherwise acquire necessary technologies could materially and adversely affect our business, financial
condition and results of operations.

11

If we cannot meet requirements
under our in-license agreements, we could lose the rights to any of our therapeutic candidates, which could have a material adverse effect
on our business.

We depend on in-licensing agreements with third parties to maintain
the intellectual property rights to our therapeutic candidates. We have in-licensed rights from Biokine Therapeutics Ltd., or Biokine,
with respect to our motixafortide therapeutic candidate; and from Innovative Pharmaceutical Concepts, Inc., or IPC, with respect to our
BL-5010 therapeutic candidate. See “ Item 4. B. Information on the Company - Business Overview - In-Licensing Agreements.”
Our in-license agreements require us to make payments and satisfy performance obligations in order to maintain our rights under these
agreements. These in-license agreements last either throughout the life of the patents that are the subject of the agreements, or with
respect to other licensed technology, for a number of years after the first commercial sale of the relevant product. In addition, we are
responsible for the cost of filing and prosecuting certain patent applications and maintaining certain issued patents licensed to us.
On June 16, 2024, Biokine filed a complaint with the District Court of Jerusalem against us. The complaint alleges breach of contract
and a purported failure to make certain payments to Biokine under our in-licensing agreement with Biokine for motixafortide. The lawsuit
seeks compensatory damages in the amount of approximately $6.5 million and a declaratory judgment in favor of Biokine. On November
20, 2024, we and Biokine entered into an agreement to refer the dispute to arbitration. See “ Item 8. Financial Information - 
Biokine Claim.”